Radiotherapy of regional epidermoid carcinoma of the lung: A study in fractionation

Sealy, R.; Lagakos, Stephen W.; Barkley, Thomas; Ryall, R. D. H.; Tucker, Robert D.; Lee, Robert E.; Ehlers, G

doi:10.1002/1097-0142(19820401)49:7<1338::aid-cncr2820490705>3.0.co;2-y

Cited by 37 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than one‐third of NSCLC patients presented with locally advanced tumors, without distant metastatic disease, which could not be primarily resected . Radiotherapy is usually used as the primary local treatment but has associated unsatisfying survival rates . Locally recurrent tumors and their complications account for about 75% of the deaths in patients with epidermoid lung cancer, and approximately 40% of the deaths in patients with other histologic subtypes of NSCLC .…”

Section: Discussionmentioning

confidence: 99%

“…16 Radiotherapy is usually used as the primary local treatment but has associated unsatisfying survival rates. [17][18][19][20] Locally recurrent tumors and their complications account for about 75% of the deaths in patients with epidermoid lung cancer, and approximately 40% of the deaths in patients with other histologic subtypes of NSCLC. 21,22 To have an impact on the overall outcome of the management of patients with localized NSCLC, one should make an attempt to decrease the probability of local failure as well as distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database

et al. 2018

View full text Add to dashboard Cite

BackgroundThere are several therapeutic strategies for the management of resectable stage IIIA/N2 non‐small‐cell lung cancer (NSCLC) patients. However, the role of radiotherapy as a preoperative adjuvant therapy is unclear.MethodsWe retrospectively analyzed the data of stage IIIA/N2 NSCLC patients who either underwent preoperative radiation (PrORT), or did not undergo preoperative radiation, collected from the Surveillance, Epidemiology and End Results (SEER) database, between 2004 and 2013. The primary endpoints were cancer‐specific survival (CSS) and overall survival (OS).ResultsUltimately, 493 patients treated with preoperative radiation and 2675 patients treated who were not treated with preoperative radiation, were included in the analysis. Overall, preoperative radiation was associated with a better CSS (HR: 1.427 [1.297‐1.572], P = 0.014) and OS (HR: 1.220 [1.131‐1.493], P = 0.002) than that observed in patients who did not undergo preoperative radiation. After PSM, preoperative radiation still showed advantage in both CSS and OS. Only age, T stage, and preoperative radiation remained independent prognostic factors for both OS and CSS. In the subgroup analysis, the advantages of preoperative radiotherapy were more pronounced in patients with stage T3 tumors and highly differentiated tumors.ConclusionsPreoperative radiation may improve the outcomes of resectable IIIA/N2 NSCLC patients. In IIIA/N2 NSCLC patients, particularly with T3 and highly differentiated tumors, clinicians should boldly apply preoperative radiotherapy to improve the patients' survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database

et al. 2018

View full text Add to dashboard Cite

show abstract

“…SQCLC indicates expanded expression of ligands for PD-1 known as PD-L1. Blocking either the receptor or ligand could defeat invulnerable resistance prompting tumor relapse [59][60][61][62][63]. Nivolumab is a human IgG4 PD-1 antibody agent which was affirmed for second line treatment of metastatic SQCLC in April 2015.…”

Section: Immunotherapymentioning

confidence: 99%

“…The mortality rate of lung cancer is very high and almost 1 in 5 cancer patients [1,2]. There are 2,24,210 new cases and 1, 59,260 deaths are reported in the year 2014 [3]. Basically there are two major types of lung cancer viz.…”

Section: Introductionmentioning

confidence: 99%

Lung Cancer: Brief Account of Advanced and Traditional Treatments and Diagnosis

Shaikh¹,

Bangal²,

Rituja³

et al. 2016

Arch Can Res

View full text Add to dashboard Cite

Lung cancer is an uncontrolled growth of lung cells that's lead to form a tumour. More than 20% of total cancer death is due to lung cancer. There are mainly two types of effective treatments available viz. traditional and advance. Each treatment has their pros and cons, but the advance and latest treatment has upper hand as well as effective results compared to the traditional one. Both Traditional chemotherapy and radiotherapy have restricted impact on advance stage of cancer. This review provides comparative account of traditional and advances in lung cancer treatment.

show abstract

“…Thus, it was the current treatment of potentially curable lung cancer at the Mayo Clinic (Lee, 1983). The side effects of this short course radiation regimen were compared to those of a less intensive schedule, delivering 50Gy in 15 fractions in 3 weeks plus 10 fractions in 2 weeks, with 2 weeks rest (Sealy et al, 1982). The toxicity was acceptable in both treatment groups and no significant differences were observed.…”

Section: Evaluation Of Responsementioning

confidence: 99%

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up

1987

Lung Cancer

View full text Add to dashboard Cite

Summary One hundred and forty-five patients with limited stage small cell lung cancer were included in a randomized trial to evaluate the effect of chemotherapy with or without chest irradiation. Seventy-six patients were allotted chemotherapy alone while 69 patients received the same chemotherapy plus radiotherapy, 40 Gy in split-course, administered in weeks 6 and 10 after the initiation of chemotherapy. The chemotherapy consisted of lomustine, cyclophosphamide, vincristine and methotrexate. Patients treated with chemotherapy alone survived for a median of 52 weeks compared to 44 weeks in patients receiving the combined regimen (P=0.055). After exclusion of five early deaths and one patient refusing the irradiation plus 14 completely resected patients, the remaining 65 patients receiving chemotherapy alone and the 60 patients treated with chemotherapy plus radiotherapy were included in a new analysis. The difference in survival duration which could be ascribed to treatment with or without chest irradiation thereby diminished (P=0.24). Eighteen months' disease-free survival was obtained in 9.2% of the 65 patients and in 9.8% of the 60 patients. The complete remission rates were 37% and 46%, respectively, (P=0.33) and the median durations of complete remission were 40 weeks and 52 weeks (P=0.67). Treatment failure of the primary tumour occurred in 85% of patients treated with chemotherapy alone in contrast to 61% of patients receiving the combined regimen (P=0.005). Seventy-nine of these patients underwent autopsy at which no residual chest disease was observed in 17% and 37%, respectively (P=0.045). The combined regimen was more toxic than chemotherapy alone resulting in significantly greater dose reductions and more pronounced thrombocytopenia. Lung and pericardial fibrosis was responsible for four deaths among the complete responders in the radiotherapy group.The combined regimen thus tended to be more efficacious with respect to tumour control at the expense, however, of increased toxicity which per se, eliminated a potential improvement of the overall therapeutical results.

show abstract

Radiotherapy of regional epidermoid carcinoma of the lung: A study in fractionation

Cited by 37 publications

References 15 publications

Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database

Preoperative radiation may improve the outcomes of resectable IIIA/N2 non‐small‐cell lung cancer patients: A propensity score matching‐based analysis from surveillance, epidemiology, and end results database

Lung Cancer: Brief Account of Advanced and Traditional Treatments and Diagnosis

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up

Contact Info

Product

Resources

About